|UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-QSB
|--------------------------------------------------------------------------------

|(Mark One) |  |                                                                                  
|---------- |  | ---------------------------------------------------------------------------------
|[X]        |  | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|           |  | For the quarterly period ended March 31, 2006                                    
|[ ]        |  | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT                  
|           |  | For the transition period from                                                   
|           |  | COMMISSION FILE NUMBER:                                                          
|           |  |                                                                                  

|MEDICALINTERNATIONALTECHNOLOGY, INC.                                              
|----------------------------------------------------------------------------------
|                                                                                  
|(Exact name of small business issuer as specified in its charter)                 
|                                                                                  
|Colorado                                                                          
|                                                                                  
|(State or other jurisdiction of incorporation or organization)                    
|                                                                                  
|                                                                                  
|2281 Guenette, Ville Saint-Laurent                                                
|Montreal, Quebec, Canada HR4 2E9                                                  
|(Address of principal executive offices)                                          
|                                                                                  
|(514) 339-9355                                                                    
|                                                                                  
|(Issuer's telephone number)                                                       
|                                                                                  
|                                                                                  
|                                                                                  
|(Former name, former address and former fiscal year, if changed since last report)

|Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 
|----------------------------------------------------------------------------------------------------------------------------------
|months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
|requirements for the past 90 days.                                                                                                
|                                                                                                                                  
|Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).                  
|                                                                                                                                  

| | The number of shares outstanding of each of the issuer's classes of common equity as of May 9, 2006:10,857,737 shares of common stock
| | -------------------------------------------------------------------------------------------------------------------------------------

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]

1

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.QUARTERLYFINANCIALREPORTIndex
|----------------------------------------------------------------

|           |  |                                                             |  | Page  
|---------- |  | ----------------------------------------------------------- |  | ------
|           |  |                                                             |  | Number
|PART I.    |  | FINANCIAL INFORMATION                                       |  |       
|Item 1.    |  | Financial Statements                                        |  |       
|           |  | Consolidated Balance Sheet (unaudited)                      |  | 3     
|           |  | Consolidated Statements of Operations (unaudited)           |  | 4     
|           |  | Consolidated Statements of Cash Flows (unaudited)           |  | 5     
|           |  | Consolidated Statements of Comprehensive Loss               |  | 6     
|           |  | Consolidated Statement of Stockholders Deficit             |  | 7     
|           |  | Notes to Consolidated Financial Statements (unaudited)      |  | 8     
|Item 2.    |  | Management's Discussion and Analysis of Financial Condition |  |       
|           |  | and Plan of Operations                                      |  | 12    
|Item 3.    |  | Controls and Procedures                                     |  | 14    
|Part II.   |  | OTHER INFORMATION                                           |  |       
|Item 1.    |  | Legal Proceedings                                           |  | 15    
|Item 2.    |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 15    
|Item 3.    |  | Defaults Upon Senior Securities                             |  | 15    
|Item 4.    |  | Submission of Matters to a Vote of Security Holders         |  | 15    
|Item 5.    |  | Other Information                                           |  | 15    
|Item 6.    |  | Exhibits and Reports on Form 8-K                            |  | 16    
|SIGNATURES |  | 16                                                         

2

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.CONSOLIDATEDBALANCESHEETMARCH31,2006(UNAUDITED)
|----------------------------------------------------------------------------------

|                                                                  |  | March 31, 2006 |  | September 30, 2005
|----------------------------------------------------------------- |  | -------------- |  | ------------------
|                                                                  |  |                |  | (Unaudited)       
|Assets                                                            |  |                |  |                   
|Current Assets                                                    |  |                |  |                   
|Cash and cash equivalents                                         |  | $              |  | 339,350           
|Accounts receivable                                               |  |                |  | -                 
|Inventories                                                       |  |                |  | 104,621           
|Research tax credit receivable                                    |  |                |  | 222,652           
|Prepaid expenses                                                  |  |                |  | 5,141             
|                                                                  |  |                |  |                   
|Total Current Assets                                              |  |                |  | 671,764           
|Property and Equipment                                            |  |                |  |                   
|Tooling and machinery                                             |  |                |  | 225,175           
|Furniture and office equipment                                    |  |                |  | 60,875            
|Leasehold improvements                                            |  |                |  | 22,163            
|                                                                  |  |                |  |                   
|                                                                  |  |                |  | 308,213           
|Less accumulated depreciation                                     |  |                |  | (180,266)         
|                                                                  |  |                |  |                   
|                                                                  |  |                |  | 127,947           
|Other Assets                                                      |  |                |  |                   
|Intangible assets subject to amortization                         |  |                |  |                   
|Patents (net accumulated amortization of $660, $601)              |  |                |  | 1,738             
|                                                                  |  |                |  |                   
|                                                                  |  |                |  | 1,738             
|                                                                 
|Total Assets                                                      |  | $              |  | 801,449           
|                                                                  |  |                |  |                   
|Liabilities and Stockholders (Deficit)                           |  |                |  |                   
|Current Liabilities                                               |  |                |  |                   
|Unearned income                                                   |  | $              |  | 109,474           
|Accounts payable                                                  |  |                |  | 198,818           
|Accounts payable  related parties                                |  |                |  | 68,489            
|Accrued expenses                                                  |  |                |  | 8,768             
|Taxes payable                                                     |  |                |  | 4,608             
|Loans payable  related parties                                   |  |                |  | 307,660           
|Current portion of long-term debt                                 |  |                |  | 7,455             
|                                                                  |  |                |  |                   
|Total Current Liabilities                                         |  |                |  | 705,272           
|Long-term debt                                                    |  |                |  | -                 
|                                                                  |  |                |  |                   
|Total Liabilities                                                 |  |                |  | 705,272           
|Stockholders Equity (Deficit)                                    |  |                |  |                   
|Preferred stock, $0.0001 par valued; 3,000,000 shares authorized; |  |                |  |                   
|none issued and outstanding as of March 31, 2006                  |  |                |  |                   
|Common stock, $0.0001 par value; 100,000,000 shares authorized;   |  |                |  |                   
|10,657,737 shares issued and outstanding as of March 31, 2006     |  |                |  | 1,065             
|Additional paid-in capital                                        |  |                |  | 5,821,101         
|Retained deficit                                                  |  |                |  | (5,658,930)       
|Other comprehensive loss                                          |  |                |  | (67,059)          
|                                                                  |  |                |  |                   
|Total Stockholders Equity (Deficit)                              |  |                |  | 96,177            
|Total Liabilities and Stockholders (Deficit)                     |  | $              |  | 801,449           
|                                                                  |  |                |  |                   

The accompanying notes are an integral part of these consolidated financial statements.

3

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.CONSOLIDATEDSTATEMENTS OFOPERATIONS(UNAUDITED)
|---------------------------------------------------------------------------------

|                                              |  | For the Three-Months Ended |  | For the Six-Months Ended
|--------------------------------------------- |  | -------------------------- |  | ------------------------
|                                              |  | March 31,                  |  |                         
|                                              |  | 2006                       |  |                         
|                                              |  |                            |  |                         
|                                              |  | (Unaudited)                |  | (Unaudited)             
|Sales                                         |  | $ 61,347                   |  | $                       
|Cost of sales                                 |  | 31,125                     |  |                         
|                                              |  |                            |  |                         
|Gross profit                                  |  | 30,222                     |  |                         
|Research and development costs                |  | 93,925                     |  |                         
|Selling, general, and administrative expenses |  | 474,560                    |  |                         
|                                              |  |                            |  |                         
|                                              |  | 568,485                    |  |                         
|Net loss before consulting fees               |  | (538,263)                  |  |                         
|Consulting fees (non-cash)                    |  | 122,600                    |  |                         
|                                              |  |                            |  |                         
|Net loss from operations                      |  | (660,863)                  |  |                         
|                                             
|Other Income (Expense)                        |  |                            |  |                         
|Interest income                               |  | (350)                      |  |                         
|Interest expense                              |  | 7,455                      |  |                         
|                                              |  |                            |  |                         
|Net Loss                                      |  | $ (667,968)                |  | $                       
|                                              |  |                            |  |                         
|                                             
|Basic weighted average shares outstanding     |  | 7,639,750                  |  | 4,621,311               
|Basic (loss) per share                        |  | $ (0.09)                   |  | $                       
|                                              |  |                            |  |                         

The accompanying notes are an integral part of these consolidated financial statements.

4

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.CONSOLIDATEDSTATEMENTS OFCASHFLOWS(UNAUDITED)
|--------------------------------------------------------------------------------

|                                                             |  |                |  | For the Six-Months Ended
|------------------------------------------------------------ |  | -------------- |  | ------------------------
|                                                             |  | March 31, 2006 |  | March 31, 2005          
|                                                             |  |                |  | (Unaudited)             
|Cash Flows from Operating Activities                         |  |                |  |                         
|Net Loss                                                     |  | $ (1,133,084)  |  | $                       
|Adjustments to reconcile net loss to net cash                |  |                |  |                         
|used in operating activities:                                |  |                |  |                         
|Depreciation and amortization expense                        |  |                |  | 22,032                  
|Common stock issued for consulting and legal services        |  |                |  | 233,176                 
|Common stock for debt                                        |  |                |  | 241,999                 
|                                                            
|Decrease in accounts receivable                              |  |                |  | 35,294                  
|Increase in receivable from taxing authorities               |  |                |  | (27,740)                
|(Increase) Decrease in inventories                           |  |                |  | (7,198)                 
|Increase in prepaid expenses                                 |  |                |  | (5,141)                 
|Decrease in unearned income                                  |  |                |  | (7,063)                 
|Increase (Decrease) in accounts payable and accrued expenses |  |                |  | (332,369)               
|Increase in taxes payable                                    |  |                |  | 4,608                   
|                                                             |  |                |  |                         
|Net Cash Used In Operating Activities                        |  |                |  | (975,486)               
|                                                             |  |                |  |                         
|                                                            
|Cash Flows from Investing Activities                         |  |                |  |                         
|Equipment acquisition                                        |  |                |  | (22,630)                
|                                                             |  |                |  |                         
|Net cash provided (used in) investing activities             |  |                |  | (22,630)                
|                                                             |  |                |  |                         
|                                                            
|Cash Flows from Financing Activities                         |  |                |  |                         
|Gross proceeds from private offerings                        |  |                |  | 1,426,005               
|Advances from loans                                          |  |                |  | -                       
|Advances (repayments) from related parties                   |  |                |  | (54,038)                
|Principal reduction on small business loan                   |  |                |  | (9,029)                 
|                                                             |  |                |  |                         
|Net cash provided by Financing Activities                    |  |                |  | 1,362,938               
|                                                             |  |                |  |                         
|                                                            
|Effect of exchange rates on cash                             |  |                |  | (31,346)                
|                                                             |  |                |  |                         
|                                                            
|Net Increase in Cash and Cash Equivalents                    |  |                |  | 333,476                 
|                                                            
|Beginning Balance  Cash and Cash Equivalents                |  |                |  | 5,874                   
|                                                             |  |                |  |                         
|                                                            
|Ending Balance  Cash and Cash Equivalents                   |  | $              |  | 339,350                 
|                                                             |  |                |  |                         
|                                                            
|                                                            
|Supplemental Information:                                    |  |                |  |                         
|Cash Paid For:                                               |  |                |  |                         
|Interest Expenses                                            |  | $              |  | 18,140                  
|                                                             |  |                |  |                         
|Income Taxes                                                 |  | $              |  | -                       
|                                                             |  |                |  |                         

The accompanying notes are an integral part of these consolidated financial statements.

5

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.CONSOLIDATEDSTATEMENTS OFCOMPREHENSIVELOSS
|-----------------------------------------------------------------------------

|                                        |  |                          |  |               |  | For the Year Ended
|--------------------------------------- |  | ------------------------ |  | ------------- |  | ------------------
|                                        |  | For the Six-Months Ended |  | September 30,
|                                        |  |                          |  | 2006          |  | 2005              
|                                        |  |                          |  |               |  |                   
|                                       
|Net loss                                |  | $                        |  | (1,133,084)   |  | $ (734,478)       
|Other comprehensive income (loss)       |  |                          |  |               |  |                   
|Foreign currency translation adjustment |  |                          |  | (67,059)      |  | 49,723            
|                                        |  |                          |  |               |  |                   
|                                       
|Net comprehensive loss                  |  | $                        |  | (1,200,143)   |  | $ (684,755)       
|                                        |  |                          |  |               |  |                   

The accompanying notes are an integral part of these consolidated financial statements.

6

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.CONSOLIDATEDSTATEMENTS OFSTOCKHOLDERSDEFICIT
|--------------------------------------------------------------------------------

|                                               |  |              |  |         |  |        |  | Additional  |  |              
|---------------------------------------------- |  | ------------ |  | ------- |  | ------ |  | ----------- |  | -------------
|                                               |  | Common Stock |  | Paid-In |  |       
|                                               |  | Shares       |  |         |  | Amount |  | Capital     |  | Deficit      
|                                               |  |              |  |         |  |        |  |             |  |              
|Balance  September 30, 2002                   |  | 1,821,680    |  | $       |  | 182    |  | $ 693,993   |  | $ (680,261)  
|                                              
|Shares issued for cash                         |  | 60,000       |  |         |  | 6      |  | 188,038     |  | -            
|Shares issued for services                     |  | 289,880      |  |         |  | 29     |  | 1,189,603   |  | -            
|Net loss for the year ended September 30, 2003 |  | -            |  |         |  | -      |  | -           |  | (1,696,421)  
|                                               |  |              |  |         |  |        |  |             |  |              
|                                              
|Balance  September 30, 2003                   |  | 2,171,560    |  | $       |  | 217    |  | $ 2,071,634 |  | $ (2,376,682)
|                                              
|Shares issued for debts                        |  | 846,226      |  |         |  | 85     |  | 610,177     |  | -            
|Shares issued for services                     |  | 1,565,515    |  |         |  | 156    |  | 1,144,106   |  | -            
|Net loss for the year ended September 30, 2004 |  | -            |  |         |  | -      |  | -           |  | (1,414,686)  
|                                               |  |              |  |         |  |        |  |             |  |              
|                                              
|Balance  September 30, 2004                   |  | 4,583,301    |  | $       |  | 458    |  | $ 3,825,917 |  | $ (3,791,368)
|                                              
|Shares issued for debts                        |  | -            |  |         |  | -      |  | -           |  | -            
|Shares issued for services                     |  | 161,124      |  |         |  | 16     |  | 94,595      |  | -            
|Net loss for the year ended September 30, 2005 |  | -            |  |         |  | -      |  | -           |  | (734,478)    
|                                               |  |              |  |         |  |        |  |             |  |              
|                                              
|Balance  September 30, 2005                   |  | 4,744,425    |  | $       |  | 474    |  | $ 3,920,512 |  | $ (4,525,846)
|                                              
|Shares issued for debts                        |  | 930,707      |  |         |  | 93     |  | 241,906     |  | -            
|Shares issued for services                     |  | 708,605      |  |         |  | 71     |  | 233,105     |  | -            
|Shares issued private placements               |  | 4,274,000    |  |         |  | 427    |  | 1,425,578   |  | -            
|                                              
|Net loss for the period ended March 31, 2006   |  | -            |  |         |  | -      |  | -           |  | (1,133,084)  
|                                               |  |              |  |         |  |        |  |             |  |              
|                                              
|Balance  March 31, 2006                       |  | 10,657,737   |  | $       |  | 1,065  |  | $ 5,821,101 |  | $ (5,658,930)
|                                               |  |              |  |         |  |        |  |             |  |              

The accompanying notes are an integral part of these consolidated financial statements.

7

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.NOTES TOUNAUDITEDCONSOLIDATEDFINANCIALSTATEMENTS
|-----------------------------------------------------------------------------------

Note 1  Basis of Presentation Interim Financial Statements

The accompanying unaudited consolidated financial statements are presented in accordance with the requirements for Form 10-QSB and Article 10 of Regulation S-X and Regulation S-B. Accordingly, they do not include all the
disclosures normally required by generally accepted accounting principles. Reference should be made to the Medical International Technology, Inc. (the "Company") Form 10KSB for the year ended September 30, 2005, and the Form 10-QSB for the
quarter ended December 31, 2005, for additional disclosures including a summary of the Company's accounting policies, which have not significantly changed.

Note 2  Summary of Significant Accounting Policies Principles of consolidation

The accompanying consolidated financial statements include the accounts and transactions of Medical International Technology, Inc. and its wholly owned subsidiary, Medical International Technologies (MIT Canada) Inc.
Intercompany transactions and balances have been eliminated in consolidation.

Foreign Currency Translations

The Company operates out of its offices in Montreal, Canada and maintains its books and records in Canadian Dollars. The consolidated financial statements herein have been converted into U.S. Dollars. Balance sheet accounts
are translated at exchange rates in effect at the end of the period and income statement accounts have been translated at average exchange rates for the period. Translation gains and losses are included as a separate component of stockholders
equity.

Allowance for Doubtful Accounts

The allowance for doubtful accounts on accounts receivable is charged to income in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable
losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectibility is determined to be
permanently impaired. As of March 31, 2006 , the Company did not establish any reserve for doubtful accounts.

Inventories

Inventories are stated at the lower of cost determined by the FIFO method or market.

Property and Equipment

The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes
and on the declining balance method for income tax reporting purposes. Depreciation expense for the Six months ended March 31, 2006 and 2005 were $21,583, and $20,000, respectively.

Intangible assets

Patents are being amortized over their respective remaining lives ranging from 9.5 years through 17 years.

Net Loss Per Share

The Company adopted the provisions of Statement of Financial Accounting Standards (SFAS) No. 128, Earnings Per Share (EPS) that established standards for the computation, presentation and
disclosure of earnings per share, replacing the presentation of Primary EPS with a presentation of Basic EPS.

8

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.NOTES TOUNAUDITEDCONSOLIDATEDFINANCIALSTATEMENTS
|-----------------------------------------------------------------------------------

Issuances Involving Non-cash Consideration

All issuances of the Companys stock for non-cash consideration have been assigned a dollar amount equaling either the market value of the shares issued or the value of consideration received whichever is more readily
determinable.

Cash and Cash Equivalents

For purpose of the statements of cash flows, the Company considers cash and cash equivalents to include all stable, highly liquid investments with maturities of three months or less.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Long-Lived Assets

In August 2001, SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," was issued establishing new rules and clarifying implementation issues with SFAS No. 121, "Accounting for the Impairment of
Long-Lived Assets and for Long-Lived Assets to be Disposed of, "by allowing a probability-weighted cash flow estimation approach to measure the impairment loss of a long-lived asset. The statement also established new standards for accounting for
discontinued operations. Transactions that qualify for reporting in discontinued operations include the disposal of a component of an entity's operations that comprises operations and cash flow that can be clearly distinguished, operationally and
for financial reporting purposes, from the rest of the entity. The Company has adopted this standard and its adoption had no significant effect on the Company's financial statements

Reclassification

Certain amounts in March 31, 2005 have been reclassified to conform to the March 31, 2006 presentation. Such reclassification had no effect on net income as previously reported.

Income Taxes

The Company accounts for its income taxes under the provisions of Statement of Financial Accounting Standards 109 ("SFAS 109"). The method of accounting for income taxes under SFAS 109 is an asset and liability method. The
asset and liability method requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between tax bases and financial reporting bases of other assets and liabilities.

Fair Value of Financial Instruments

Pursuant to SFAS No. 107, Disclosures About Fair Value of Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheet as of March 31,
2006. The Company considers the carrying value of such amounts in the financial statements to approximate their face value.

Revenue Recognition

The Company recognizes revenue when the related product is shipped to the respective customer.

Note 3 - Intangible Assets

Amortization expense for the Six-months ended March 31, 2006 and 2005 were $59, and $116, respectively.

9

---

MEDICALINTERNATIONALTECHNOLOGY,INC.

NOTES TOUNAUDITEDCONSOLIDATEDFINANCIALSTATEMENTS

Note 4 - Stock Activity

On November 17, 2005, Shareholders, at a Special Shareholders Meeting, approved a 1 for 10 reverse split of the Companys issued and outstanding stock. On November 21, 2005, subsequent to the reverse-split the
Company was issued a new trading symbol. The new trading symbol is MDLH.

On November 30, 2005 the Company issued 520,000 post-reverse split restricted common shares at a price of $0.25 per share to Idee International R & D Inc., a company owned as to 100% by Karim Menassa for a debt
conversion of $130,000 in a transaction exempt from registration under Regulation S of the Securities Act of 1933 and subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

On November 30, 2005 the Company issued 128,000 post-reverse split restricted common shares at a price of $0.25 per share to Karim Menassa, a Director and Officer of the Company for a debt conversion of $32,000 in a
transaction exempt from registration under Regulation S of the Securities Act of 1933 and subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144 On November 30, 2005 the Company
issued 52,000 post split restricted common shares at a price of $0.25 per share to Technopro M.S. (2999226 Canada Inc.), for a debt conversion of $13,000 in a transaction exempt from registration under Regulation S of the
Securities Act of 1933 and subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

On December 7, 2005, the Company completed two rounds of financing. All the Units in these offerings were sold in exempt transactions under Regulation S of the Securities Act of 1933 and are subject to Rule 144
of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

The first private placement consisted of 2,000,000 Units at a price of $0.25 per unit. Each unit consisted of one Series A Warrant for the purchase of 2,000,000 shares of the Companys common stock at an exercise
price of $0.75 per share and one Series B Warrant for the purchase of 2,000,000 shares of the Companys common stock at an exercise price of $1.00 per share. Both the series A and series B warrants expire on October 27, 2007. The total
amount raised from this placement was $500,000 of which the company was obligated to pay an 8% finder fee to Group InterCapital, Inc.,a consulting firm. Net proceeds to the company less the $40,000 finder fee were $460,000.The purchaser
of this offering was a Canadian entity controlled by a daughter of the individual controlling the consulting firm. These Units were sold in an exempt transaction under Regulation S of the Securities Act of 1933 and are subject to Rule
144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

The second private placement was for 1,224,000 Units at a price of $0.25 per Unit. Each unit of this second offering consisted of one Series A Warrant for the purchase of 1,224,000 shares of the Companys common
stock at an exercise price of $0.75 per share and one Series B Warrant for the purchase of 1,224,000 shares of the Companys common stock at an exercise price of $1.00 per share. Both the series a and series B warrants expire on
November 07, 2007. The total amount raised from this placement was $306,000 of which the company is obligated to pay an 8% finder fee to Group InterCapital, Inc., a consulting firm. Net proceeds to the company less the $24,480 finder fee
were $281,520. These Units were sold in an exempt transaction under Regulation S of the Securities Act of 1933 and are subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

On December 20, 2005, the company sold in a private placement 1,000,000 Units at a price of $0.60 per Unit. Each unit sold in this offering includes one (1) Series A Warrant for a total of 1,000,000 shares of the
Company's common stock at an exercise price of $0.75 per share The series A warrant expires on December 19, 2007. The total amount raised from this placement was $600,000 of which the company is obligated to pay a 9% finder fee to 9109-7923
Quebec Inc. Net proceeds to the company less the $54,000 finder fee were $546,000. . These Units were sold in an exempt transaction under Regulation S of the Securities Act of 1933 and are subject to Rule 144 of the Securities
Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

On February 27, 2006, the company issued 153,400 shares to 2849674 Canada Inc., a company owned as to 100% by Karim Menassa, a director and officer, for a debt conversion of $61,300 in a transaction exempt from
registration under Regulation S of the Securities Act of 1933 and subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144

10

---



|MEDICALINTERNATIONALTECHNOLOGY,INC.NOTES TOUNAUDITEDCONSOLIDATEDFINANCIALSTATEMENTS
|-----------------------------------------------------------------------------------

Additionally, on February 27, 2006, the company issued 153,400 shares to 1065029 Canada Inc., a company owned as to 100% by Michel Bayouk, a director, for a debt conversion of $61,300 in a transaction exempt from
registration under Regulation S of the Securities Act of 1933 and subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

On March 14, the company issued 25,000 unrestricted common shares to Geoffrey Armstrong, an employee for the exercise of options at a price of $0.40 per share pursuant to a Form S-8 registration filed December 27,
2005. On March 24, the company issued 25,000 unrestricted common shares and on April 21, 2006 an additional 200,000 unrestricted common shares to Geoffrey Armstrong, an employee for the exercise of options at a price of $0.40 per share pursuant
to the Form S-8 registration filed December 27, 2005.

Note 5 - Related Party Transactions

On January 31st, 2002, Idee International R&D Inc. (Idee), a company wholly owned by a majority shareholder of MIT, sold the companys
tooling, machinery, and other property for $146,331. the purchase price, in addition to an outstanding loan of approximately $99,825 due to Idee have been combined and are evidenced by a non-recourse promissory note bearing interest at an
annual rate of 11.5% . Principal and accrued interest are payable on demand only after the company becomes profitable and the repayment of such loan does not impact the companys ability to operate and meet its normal obligation.

Interest was paid to a company under common control, Idee , of $18,140 for the period ended March 31, 2006 and $26,954 for the year ended September 30, 2005. The balance due as at March 31, 2005 is $297,132 and
as at September 30, 2005 is $297,132.

During the period the company repaid advances to a company under common control, Scanview Corporation Inc, of $200,000. The balance due as at March 31, 2006 is $10,468 and as at September 30, 2005 is $210,468.
The advance is non-interest bearing with no specific repayment terms.

11

---

MEDICALINTERNATIONALTECHNOLOGY,INC.  QUARTERLYFINANCIALREPORT

Item 2. Management's Discussion and Analysis of Financial Condition and Plan of Operations

All statements that are included in this Quarterly Report, other than statements of historical fact, are forward looking statements. You can identify forward-looking statements by words such as anticipate,
believe and similar expressions and statements regarding our business strategy, plans and objectives for future operations. Although management believes that the expectations reflected in these forward looking statements are reasonable,
it can give no assurance that such expectations will prove to have been correct. The forward-looking statements in this filing involve known risks and uncertainties, which may cause our actual results in future periods to be materially different
from any future performance suggested in this report. Such factors may include, but are not limited to: the ability to obtain additional funding further develop and market our products, changes in technology, market acceptance of our products,
regulatory approval of our products in various markets, fluctuations in customer demand and commitments, pricing and competition, reliance upon subcontractors, together with such other factors as may be included in our Annual Report on Form 10-KSB.

Financial Summary

Results of Operations for the Three-Months Ended March 31, 2006 and 2005

For the three-months ended March 31, 2006, the Company experienced a net loss from operations of $667,968, primarily comprised of research and development expenses of $93,925 and selling, general and administrative
expenses of $474,560. For the three-months ended March 31, 2005, the Companys net loss from operations was $105,080.

Selling, general and administrative expenses for the three-months ended March 31, 2006 were $474,560, compared to $48,905 for the three-months ended March 31, 2005.

For the three-months ended March 31, 2006, the Companys sales were $61,347 resulting in a decrease in sales of $19,501 compared to sales for the three-months ended March 31, 2005.

Gross profit for the three-months ended March 31, 2006 was $30,222 or 49% of sales as compared to 61% for the three-months ended March 31, 2005. MIT uses machined components in our products resulting in reduced unit
costs as order volumes increase. Small quantity and customized orders significantly impact the gross profit derived from the sale of our products.

As of March 31, 2006, the Company maintains $64,656 as advances towards future sales pertaining to its non-exclusive distribution agreement with WLT Distributors Inc.

Liquidity and Capital Resources

For the six months ended March 31, 2006 the Companys cash position increased by $333,476. The Company spent $975,486 from its operations and received $1,362,938 from financing activities. Financing
activities included an amount repaid to related parties of $54,038.

For the six months ended March 31, 2005 the Companys cash position increased by $33,239. The Company spent $115,614 from its operations and received $142,978 from financing activities. Financing activities
included the repayments of its principal amount of its business loan of $7,268.

Medical International Technology, Inc. expects that revenues from existing and developing sales may not meet its liquidity requirements for the next 12 month period at its current level of operations. The company continues
to rely on management to develop the business and work to develop sales. Management has and may continue to supplement cash flows from sales with additional equity and debt financing. Substantially, expanded operations are expected to require
additional capital, either from a future offering of equity or the company pursuing other methods of financing, as appropriate.

12

---

MEDICALINTERNATIONALTECHNOLOGY,INC.  QUARTERLYFINANCIALREPORT

Management Plan of Operations

Medical International Technology, Inc. (MIT) is engaged in the business of research, development, marketing and sales of needle-free jet injector technology and products for humans and animals, for single and
mass injections. We continue to market our product in all available markets, seek regulatory approvals to expand those market opportunities and improve our products for application to new markets.

We have retained two Business consultants to assist in restructuring and developing new opportunities.

Medical International Technology, Inc. continues its efforts to secure additional funding to support and expand operations, develop and seek regulatory approvals for our products and market those products worldwide.

Medical International Technology, Inc. will continue to seek additional funding to expand operations and develop sales revenue to a volume sufficient to sustain operationsProduct
DevelopmentMedical International Technologies has filed for FDA approval for its needle-free injector  the MED-JET, designed specifically for human mass inoculations. The MED-JET is capable of delivering
many types of medications such as vaccines, insulin and other types of injectables. Its low-pressure technology offers an advantage to alternative high pressure systems that can cause blowbacks and expose medical workers and patients alike to
microscopic traces of blood.

According to the International Sharps Injury Prevention Society (http://www.isips.org), it has been estimated that one out of every seven workers is accidentally stuck by a contaminated sharp point each and every year. The
Center for Disease Control (CDC: http://www.cdc.gov/niosh/2000-108.html#5) estimates that there are 600,000 to 800,000 needle stick injuries per year in the U.S. alone, and many are not reported. More than 20 types of infectious agents have been
transmitted through needlesticks, including hepatitis B and C, tuberculosis, syphilis, malaria, herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The MED-JET will eliminate this risk to our health care professionals and create
a safer workplace. Other advantages include its light weight (0.5 kg) and an excellent medication absorption rate. Additionally, the system has the ability to increase or decrease the volume and pressure of injection. This technology is unique to
MITs MED-JET MBX Injector. The system is designed to allow for the injection of up to 600 individuals an hour.

The approval process can be expensive and may take an extended period of time. There can be no assurance that this system will receive approval from the FDA or if approved gain broad acceptance by the medical community or
individual patients.

On December 15, 2005, Medical International Technologies, Inc announced that it has received full certification granted under the International Organization for Standardization, as well as the Canadian Medical Device
Conformity Assessment System, for devices to be licensed by HEALTH CANADA. These certifications allow MIT to market the Med-Jet Needle-Free Injector for human use in all countries other than the U.S., at this point. The Med-Jet injector has been
submitted for FDA approval which, if accepted, will allow MIT to sell the Med-Jet in the United States, making it a truly worldwide system.

MIT's Needle-Free Injection System, designed specifically to allow fast, accurate and safe injections, is rapidly moving toward establishing itself as a valuable instrument in the fight against disease in both humans and
animals. Spurred on by growing fears of a world wide epidemic that could match or even exceed the deadly flu pandemic of 1918, which killed millions of people, the MIT team is focusing its efforts to make its Needle-Free Injection System available
to the world.

Now that MIT is able to sell its Med-Jet in all countries, other than the U.S., it is working to complete two FDA filings. The first of these will be for use of the Med-Jet for injecting anesthesia in a variety of
situations. The second, and most significant, in light of the news coming out of Asia concerning the spread of Influenza A (H5N1) to humans, will be the Med-Jet-H, for mass vaccination in case of a pandemic, such as Avian Influenza, Polio,
Tuberculosis, or Malaria .

MIT is also pursuing increasing interest in its Agro-Jet needle-free injector. Having the same benefits as Med-Jet, Agro-Jet will become a valuable instrument in the fight against Avian Flu via Med-Jets ability to
allow for the mass inoculation of animals at over 1000 injections per hour.

13

---

MEDICALINTERNATIONALTECHNOLOGY,INC.  QUARTERLYFINANCIALREPORT

On December 22, 2005 we announced that as part of its continuing restructuring program MIT is forming two divisions. The Human Medical Technology Division will focus on the development, production, marketing and sale of
needle-free injectors and other medical technologies for humans. The Animal Medical Technology Division will deal with all aspects of the development, production, marketing and sale of the needle-free injectors and other technologies for animal
applications worldwide.

On December 19, 2005 the Board of MIT adopted a resolution stating that " MIT will acquire all of the issued and outstanding shares of 9139-2449 Quebec Inc operating under the name Scanview for 2,500,000
restricted common shares of MIT". No shares have been issued and the final terms are pending acceptance by the shareholders of Scanview On December 22, 2005 we announced that MIT will proceed with the ScanView acquisition. Scanview is a portable
ultrasound technology and manufacturing company based in Montreal, Quebec, Canada. ScanView was formed in 2003 to develop, manufacture and market different models of Real Time Ultrasound Scanners, for Animal and Human applications.

ScanView has a unique, portable and battery operated ultrasound diagnostic medical device, using a variety of probes for pathological and physiological evaluation of organs such as the heart, kidneys, liver, thyroid, uterus
and ovaries. They serve equally well to detect kidney stones, diagnose pregnancy, visualize follicle development and carry out all other normal ultrasound diagnostic procedures.

ScanView is a private Canadian company owned by Karim Menassa, our CEO and Director, owning 55% of Scanview, Michel Bayouk, our CFO and Director, owning 10% of Scanview and three other unrelated shareholders.

Item 3. Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such
term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our
disclosure controls and procedures were effective as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or
are reasonably likely to materially affect, our internal controls over financial reporting

14

---

MEDICALINTERNATIONALTECHNOLOGY,INC.  QUARTERLYFINANCIALREPORT

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

None, for the period ending March 31, 2006.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On February 27, 2006, the company issued 153,400 shares, at a price of $0.40 per share, to 2849674 Canada Inc., a company owned as to 100% by Karim Menassa, a director and officer, for a debt conversion of $61,360
in a transaction exempt from registration under Regulation S of the Securities Act of 1933 and subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

Additionally, on February 27, 2006, the company issued 153,400 shares, at a price of $0.40 per share, to 1065029 Canada Inc., a company owned as to 100% by Michel Bayouk, a director, for a debt conversion of $61,360
in a transaction exempt from registration under Regulation S of the Securities Act of 1933 and subject to Rule 144 of the Securities Act of 1933, as amended. The securities are restricted pursuant to Rule 144.

These private transactions we believe to be exempt from registration Section 4(2) of the Securities Act. We also believe this private offering to be exempt from registration under Regulation S, as the purchaser is domiciled
and transaction occurred outside the United States. The sales of stock were strictly limited to individuals and entities, each of whom was an accredited investor, as that term is defined in Rule 501 of Regulation D promulgated under Section 4(2) of
the Securities Act and had adequate access to information pertaining to our Company. Furthermore, no advertisements were made, no commissions were paid and the securities are restricted pursuant to Rule 144.

Stock Incentive Plan

The company has a stock incentive plan titled Compensation under which 750,000 common shares are authorized for issuance and have been registered, as amended on Form S-8 filed December 27, 2005. The plan relates
to the Medical International Technology Stock Option Agreement dated October 1, 2005, with Geoffrey Armstrong for services, to Medical International Technology, Inc.

Under the Compensation plan, in the three month period ended March 31, 2006, the Company issued 50,000 common shares to Geoffrey Armstrong for consulting services. The Company received a total of $20,000 for
the exercise of the options at $0.40 per share. Under the Compensation plan, on April 21, 2006, the Company issued 200,000 common shares to Geoffrey Armstrong for consulting services. The Company received a total of $80,000 for
the exercise of the options at $0.40 per share. As of March 31, 2006, a total of 500,000 common shares remain authorized for issuance under the Compensation plan.

|Item 3. |  | Defaults Upon Senior Securities                         
|------- |  | --------------------------------------------------------
|        |  | None                                                    
|Item 4. |  | Submission of Matters to a Vote of Security Holders     
|        |  | None during the three month period ended March 31, 2006.
|Item 5. |  | Other Information                                       
|        |  | None                                                    

15

---

MEDICALINTERNATIONALTECHNOLOGY,INC.  QUARTERLYFINANCIALREPORT

Item 6. Exhibits and Reports on Form 8-K

| | ExhibitsMedical International Technology, Inc. includes herewith the following exhibits:31.1 Certification of Principal Executive Officer (Rule 13a-14(a)/15(d)-14(a))31.2 Certification of Principal Accounting Officer (Rule 13a-14(a)/15(d)-14(a))32.1 Certification of Principal Executive Officer (18 U.S.C. 1350)32.2 Certification of Principal Accounting Officer (18 U.S.C. 1350)Reports on Form 8-KNone during the three month period ended March 31, 2006.
| | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|                   |  | Medical International Technology, Inc.
|------------------ |  | --------------------------------------
|                  
|Date: May 18, 2006 |  | By:                                   
|                   |  |                                       
|                   |  |                                       
|                   |  |                                       
|                  
|                  
|Date: May 18, 2006 |  | By:                                   
|                   |  |                                       
|                   |  |                                       
|                   |  |                                       

16

---